The phase 2 ALTA trial [100,101] evaluated the efficacy of brigatinib in patients with advanced ALK-positive non-small cell lung carcinoma previously treated with crizotinib [100,101]. This evidence concerns the gene ALK and non-small cell lung carcinoma.